SCHEMBL2885923

SCHEMBL2885923

NC(=O)c1ncn2c(=O)n(CCC(=O)O)nnc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.63
PABPC1 P11940 1/20 0.63
KMT2A Q03164 1/20 0.63
EGLN3 Q9H6Z9 2/20 0.39
CA12 O43570 3/20 0.38
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
CA9 Q16790 3/20 0.38
KMO O15229 2/20 0.36
MAPK1 P28482 1/20 0.33
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
ESR1 P03372 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
CSNK2A1 P68400 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2892060 0.91 MEN1 (0.64) MEN1PABPC1KMT2ACA12CA1
SCHEMBL13027731 0.90 MEN1 (0.71) MEN1PABPC1KMT2ACA12CA1
SCHEMBL2889998 0.88 MEN1 (0.63) MEN1PABPC1KMT2ACA12CA1
SCHEMBL2891553 0.86 MEN1 (0.66) MEN1PABPC1KMT2ACA12CA1
SCHEMBL3334065 0.85 MEN1 (0.64) MEN1PABPC1KMT2ACA12CA1
SCHEMBL13028034 0.85 MEN1 (0.64) MEN1PABPC1KMT2ACA12CA1
Mitozolomide SCHEMBL97695 0.85 MEN1 (0.64) MEN1PABPC1KMT2ACA12CA1
SCHEMBL3336560 0.85 MEN1 (0.68) MEN1PABPC1KMT2ACA12CA1
SCHEMBL13028036 0.85 MEN1 (0.64) MEN1PABPC1KMT2ACA12CA1
SCHEMBL3337129 0.84 MEN1 (0.63) MEN1PABPC1KMT2ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2698370-A2 3-substituted-4-oxo-3,4-dihydro-imidazo-[5,1-d][1,2,3,5]-tetrazine-8-carboxylic acid amides as anticancer agents Pharminox Limited (GB) 2014-02-19 EP disclosed
US-20130338104-A1 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d]1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use PHARMINOX LIMITED (GB) 2013-12-19 US disclosed
US-8450479-B2 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use PHARMINOX LIMITED (GB) 2013-05-28 US disclosed
US-8450479-B2 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use PHARMINOX LIMITED (GB) 2013-05-28 US disclosed
US-8450479-B2 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use PHARMINOX LIMITED (GB) 2013-05-28 US disclosed
US-20100286088-A1 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use PHARMINOX LIMITED (GB) 2010-11-11 US disclosed
US-20100286088-A1 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use PHARMINOX LIMITED (GB) 2010-11-11 US disclosed
US-20100286088-A1 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use PHARMINOX LIMITED (GB) 2010-11-11 US disclosed
EP-2229393-A2 3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO-[5,1-D][1,2,3,5]-TETRAZINE-8-CARBOXYLIC ACID AMIDES AS ANTICANCER AGENTS PHARMONIX LIMITED (GB) 2010-09-22 EP disclosed
WO-2009077741-A2 3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO-[5,1-D][1,2,3,5-TETRAZINE-8-CARBOXYLIC ACID AMIDES AND THEIR USE PHARMINOX LIMITED (GB) 2009-06-25 WO disclosed
WO-2009077741-A2 3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO-[5,1-D][1,2,3,5-TETRAZINE-8-CARBOXYLIC ACID AMIDES AND THEIR USE PHARMINOX LIMITED (GB) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286088-A1 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use MKI67, CCNI, CDK4 MEN1 3049/4885PABPC1 3755/4885KMT2A 209/4885
US-20130338104-A1 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d]1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use MKI67, CCNI, CDK4 MEN1 2953/4885PABPC1 3459/4885KMT2A 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.